Physician profile
Christopher David Centafont
NPI 1447239595
$4,079.67
in general payments reported to CMS, 2019-2025
30 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $802 · 2021: $842 · 2022: $366 · 2023: $506 · 2024: $491 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $570.82 | 2019-2024 | Farxiga, Wainua |
| Pfizer INC. | $436.48 | 2019-2025 | |
| Esperion Therapeutics, INC. | $402.24 | 2020-2025 | Nexletol |
| Amgen INC. | $352.66 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $338.51 | 2019-2021 | |
| Boston Scientific Corporation | $299.90 | 2019-2024 | S-Icd System Magnet |
| Philips North America LLC | $264.15 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Novartis Pharmaceuticals Corporation | $227.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $203.88 | 2019-2024 | Camzyos |
| Medtronic, INC. | $185.68 | 2021-2024 | Onyx Frontier |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.58 | 2020-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.56 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $84.49 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $62.87 | 2022-2024 | Xarelto |
| Medtronic Vascular, INC. | $57.24 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $51.32 | 2019-2020 | |
| Vital Connect, INC | $47.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $41.30 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $36.97 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.83 | 2025 | |
| Atricure, INC. | $26.96 | 2022 | |
| Abbott Laboratories | $23.65 | 2024 | Mini Trek |
| Abiomed | $21.52 | 2024 | Impella |
| Lundbeck LLC | $19.04 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.85 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.84 | 2020 | |
| Scpharmaceuticals INC. | $13.86 | 2024 | |
| Gilead Sciences, INC. | $13.25 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.14 | 2023 | Inpefa |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Centafont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.